| Title： | Chinese Experts Consensus for Off-label Use of JAK inhibitors in the treatment of rheumatic diseases |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Clinical physicians at all levels (rheumatology, pediatrics, pharmacy, and other relevant fields) |
| Evidence classification method： | Relevant evidence on drug label, guidelines, consensuses, MICROMEDEX database, clinical studies are collected and evaluated. We evaluate the effectiveness grade, recommendation grade and evidence grade by referring to the Thomson classification system standard of Micromedex.In combination with evidence, experts of rheumatology, pediatrics and pharmacy are inquiried,and reach a consensus through the evaluation and optimization of the Delphi method. |
| Development unit： | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University |
| Registration time: | 2022-06-09 |
| Registration number： | IPGRP-2022CN321 |
| Purpose of the guideline: | The Off-label Use of JAK inhibitors in the treatment of various rheumatic diseases are increasing,but the safety concerns deserves great attention.Therefore, it is necessary to form an expert consensus on the Off-label use of JAK inhibitors, in order to further standardize the clinical application of JAK inhibitors in the treatment of rheumatic diseases. |
Latest registration
